[Gan & Lee Pharmaceuticals: The first subject was administered in the Phase I clinical trial of GLR1075 injection] On October 12, Gan & Lee Pharmaceutical (603087.SH) announced that the phase I clinical trial of GLR1075 injection independently developed by the company in China has recently successfully completed the administration of the first subject. This product is a recombinant human albumin preparation, intended for the treatment of hypoalbuminemia in liver cirrhosis and ascites. As of the date of the announcement, only Heyuan Bio's plant-derived recombinant human albumin injection (Aofumin®) has been approved for marketing by the State Food and Drug Administration in China; Tonghua Everett's yeast-derived recombinant human albumin injection has been approved for marketing in Russia and Kyrgyzstan. As of June 30, 2026, the project has invested a total of 81.9161 million yuan in research and development expenses.